Prostate cancer is the most commonly diagnosed cancer in men and the second leading cause of cancer-associated death among men in the United States. Trying to distinguish high-risk from low risk prostate cancer remains difficult, leading to over diagnosis and unnecessary invasive treatments and treatment-associated morbidity. Tests that can detect clinically significant prostate cancer while reducing over diagnosis of low-risk disease continue to be an unmet need in the clinical setting.
Multi-parametric MRI, commonly referred to as mpMRI has shown that this examination can reduce unnecessary biopsies by more than one third, and increased the detection of clinically significant disease by more than 50%. Prebiopsy mpMRI combined with targeted biopsy is associated with the improved detection of clinically significant prostate cancers, a reduction in the number of biopsy cores per procedure, and the potential to avoid unnecessary biopsies.
MR is often recommended for patients with negative biopsies, if warranted based on clinical suspicion, implying that many patients requiring a TRUS biopsy will undergo mpMRI at some stage in their clinical pathway.
Diagnostic prostate exams on the Oasis 1.2T High Field Open MR for large patients and those with hip replacements allows more diagnostic-quality exams with reduced metal susceptibility artifacts on the diffusion sequence compared to a 3T magnet. While the current technical parameters described in PI-RADS v2.1 focus on optimal technique for 1.5T and 3T magnets, we hope that we can provide enough validated data to allow multi-parametric prostate MRI on the Oasis 1.2T platform to be incorporated in newer PI-RADS guidelines, under certain conditions.
To see how we applied this to an actual patient read the Clinical Case Report: Prostate Cancer Detection on 1.2T Open Oasis MRI System.
Written by David Wilson, Director of Communications/Marketing, Fujifilm Healthcare Americas